ClinicalTrials.gg
CompletedNCT04511702Updated Oct 20, 2025Results posted

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

A Phase 4 interventional study of Pegloticase with MTX in Chronic Uncontrolled Gout, Gout and Uncontrolled Gout, sponsored by Amgen. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
191
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
4th of 14
191 · median 93
Started
2020
the only one that year
Phase 4
7 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 4, and was the 10th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.

Read the detailed description

Approximately 180 participants will be enrolled. After a 4-week methotrexate run-in period, participants will be treated for up to 24 weeks with weekly oral methotrexate and biweekly 8mg pegloticase infusions. Up to three pegloticase infusion durations will be assessed in the study: 60-minute infusion, 45-minute infusion and 30-minute infusion. Safety evaluations will be performed regularly throughout the course of the study.

Acquired from Horizon in 2024.

03

Conditions studied

  • Chronic Uncontrolled Gout
  • Gout
  • Uncontrolled Gout

Browse trials for

Keywords

  • gout
  • uncontrolled gout
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult men or women ≥18 years of age.
  2. Uncontrolled gout, defined as meeting the following criteria:

    • Hyperuricemia during the screening period defined as sUA ≥6 mg/dL
    • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with intolerable side effects or a to xanthine oxidase inhibitor therapy based on medical record review or subject interview.
    • Symptoms of gout including at least 1 of the following:

      • Presence of at least one tophus
      • Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
      • Presence of chronic gouty arthritis
  3. Willing to discontinue all oral urate-lowering therapy at least 7 days prior to MTX dosing at Week -4 and remain off of urate lowering therapy when receiving pegloticase infusions during the study.

Exclusion criteria

Exclusion Criteria:

  1. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
  2. Current or chronic treatment with systemic agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other on a chronic basis (defined as 3 months or longer) would also meet exclusion criteria.
  3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency (tested at Screening Visit).
  4. Severe chronic renal impairment (estimated \<40 mL/min/1.73 m2) at the Screening Visit based on 4 variable-Modification of Diet in Renal Disease [MDRD] formula or currently on dialysis.
  5. Non-compensated congestive heart failure or hospitalization for congestive heart failure or treatment for acute coronary syndrome (myocardial infarction or unstable angina) within 3 months of the Screening Visit, or current uncontrolled arrhythmia, or current uncontrolled blood pressure (BP) (>160/100 mmHg) prior to Week -4.
  6. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of , as determined by the Investigator.
  7. Prior treatment with pegloticase (KRYSTEXXA), another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
  8. Currently receiving systemic or radiologic treatment for ongoing cancer.
  9. History of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Pegloticase 60 Minute Infusion with methotrexate (MTX)

    Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks

    Biological: Pegloticase with MTX

  • Experimental
    Pegloticase 45 Minute Infusion with methotrexate (MTX)

    Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks

    Biological: Pegloticase with MTX

  • Experimental
    Pegloticase 30 Minute Infusion with methotrexate (MTX)

    Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks

    Biological: Pegloticase with MTX

Interventions

  • BiologicalPegloticase with MTX

    Drug pages: Pegloticase · Methotrexate

    Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period

    Also known as: Methotrexate

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24

    IRs, including anaphylaxis, were assessed after each infusion for a period of 24 weeks. IRs were defined as any infusion-related adverse event (AE) or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and up to 2 hours post-infusion. Additional AEs occurring outside of the 2-hour window following infusion could also be categorized as an IR at the Principal Investigator's discretion.

    Time frame: Day 1 to Week 24

Secondary outcomes

  1. Percentage of Serum Uric Acid (sUA) Responders at Month 6

    Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.

    Time frame: Up to 6 months

  2. Percentage of Participants Who Experienced an IR Leading to Discontinuation of Treatment, Anaphylaxis or Met sUA Discontinuation Criteria

    IRs were defined as any infusion-related AE or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and for 2 hours post-infusion. Other AEs that occurred outside of the 2 hour window following the infusion may have also been categorized as an IR at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual sUA discontinuation criteria was defined as two consecutive pre-infusion sUAs \> 6 mg/dL after Day 1.

    Time frame: Day 1 to Week 24

  3. Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in All Participants

    Infusion reactions were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. All participants were censored at the date of their last infusion.

    Time frame: Day 1 to Week 24

  4. Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in Participants With an Event

    IRs were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. Only participants who experienced an event were included in this analysis.

    Time frame: Day 1 to Week 24

07

Results

Posted Jan 7, 2025

Participant flow

Participants with uncontrolled gout were enrolled at 36 centers across the United States between October 2020 and March 2024.

Participant flow — Overall Study
MilestonePegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Started1161362
Completed961250
Not completed20112
Withdrew: Lost to follow-up304
Withdrew: Withdrawal by subject1718

Outcome measures

PrimaryPercentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24

IRs, including anaphylaxis, were assessed after each infusion for a period of 24 weeks. IRs were defined as any infusion-related adverse event (AE) or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and up to 2 hours post-infusion. Additional AEs occurring outside of the 2-hour window following infusion could also be categorized as an IR at the Principal Investigator's discretion.

Time frame:
Day 1 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24
Percentage of ParticipantsPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 246.0 (2.5 to 12.0)0 (0.0 to 24.7)12.9 (5.7 to 23.9)
SecondaryPercentage of Serum Uric Acid (sUA) Responders at Month 6

Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.

Time frame:
Up to 6 months
Reported as:
Number · Percentage of Participants
Percentage of Serum Uric Acid (sUA) Responders at Month 6
Percentage of ParticipantsPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Percentage of Serum Uric Acid (sUA) Responders at Month 667.2 (57.9 to 75.7)76.9 (46.2 to 95.0)56.5 (43.3 to 69.0)
SecondaryPercentage of Participants Who Experienced an IR Leading to Discontinuation of Treatment, Anaphylaxis or Met sUA Discontinuation Criteria

IRs were defined as any infusion-related AE or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and for 2 hours post-infusion. Other AEs that occurred outside of the 2 hour window following the infusion may have also been categorized as an IR at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual sUA discontinuation criteria was defined as two consecutive pre-infusion sUAs \> 6 mg/dL after Day 1.

Time frame:
Day 1 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an IR Leading to Discontinuation of Treatment, Anaphylaxis or Met sUA Discontinuation Criteria
Percentage of ParticipantsPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Percentage of Participants Who Experienced an IR Leading to Discontinuation of Treatment, Anaphylaxis or Met sUA Discontinuation Criteria19.0 (12.3 to 27.3)7.7 (0.2 to 36.0)32.3 (20.9 to 45.3)
SecondaryTime to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in All Participants

Infusion reactions were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. All participants were censored at the date of their last infusion.

Time frame:
Day 1 to Week 24
Reported as:
Median · Days
Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in All Participants
DaysPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in All ParticipantsNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in Participants With an Event

IRs were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. Only participants who experienced an event were included in this analysis.

Time frame:
Day 1 to Week 24
Reported as:
Median · Days
Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in Participants With an Event
DaysPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in Participants With an Event17.0 (1 to 113)15.0 (15 to 15)43.0 (15 to 144)

Adverse events

Collected over Up to approximately 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MTX Run-In0/215 (0%)1/215 (0.5%)79/215 (36.7%)
Pegloticase 60 Minute + MTX0/116 (0%)4/116 (3.4%)86/116 (74.1%)
Pegloticase 45 Minute + MTX0/13 (0%)0/13 (0%)13/13 (100%)
Pegloticase 30 Minute + MTX0/62 (0%)5/62 (8.1%)46/62 (74.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventMTX Run-InPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
Non-cardiac chest painGeneral disorders0/2150/1160/131/62
Anaphylactic reactionImmune system disorders0/2150/1160/131/62
Infusion related reactionInjury, poisoning and procedural complications0/2151/1160/131/62
GoutMetabolism and nutrition disorders0/2150/1160/131/62
ShockVascular disorders0/2150/1160/131/62
Vertigo positionalEar and labyrinth disorders0/2151/1160/130/62
Small intestinal obstructionGastrointestinal disorders0/2151/1160/130/62
COVID-19Infections and infestations0/2151/1160/130/62
Muscular weaknessMusculoskeletal and connective tissue disorders0/2151/1160/130/62
GastroenteritisInfections and infestations1/2150/1160/130/62
Most frequent other events
Showing 10 of 24
Most frequent other events
EventMTX Run-InPegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTX
GoutMetabolism and nutrition disorders72/21577/1169/1344/62
DiarrhoeaGastrointestinal disorders3/2153/1162/134/62
ArthralgiaMusculoskeletal and connective tissue disorders1/2154/1162/132/62
Pain in extremityMusculoskeletal and connective tissue disorders0/2153/1162/132/62
Infusion related reactionInjury, poisoning and procedural complications0/2156/1160/137/62
COVID-19Infections and infestations2/2154/1160/136/62
Lacrimation increasedEye disorders1/2150/1161/130/62
Abdominal painGastrointestinal disorders0/2150/1161/132/62
VomitingGastrointestinal disorders1/2150/1161/132/62
HepatotoxicityHepatobiliary disorders0/2150/1161/130/62

Baseline characteristics

Modified intent-to-treat (mITT) Analysis Set: All participants who received at least 1 dose of pegloticase.

Age, Continuous
Age, Continuous(Years)Pegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTXTotal
Mean55.2 ± 11.3361.1 ± 9.9656.9 ± 11.0456.2 ± 11.20
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTXTotal
Female122923
Male1041153168
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTXTotal
American Indian or Alaska Native0011
Asian81211
Black or African American183930
Native Hawaiian or Other Pacific Islander0011
White84948141
More than 1 race3014
Other3003
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegloticase 60 Minute + MTXPegloticase 45 Minute + MTXPegloticase 30 Minute + MTXTotal
Hispanic or Latino291434
Not Hispanic or Latino871258157
08

Study locations

39 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Orthopedic Physicians Alaska
    Anchorage, Alaska 99508, United States
  • Arizona Arthritis & Rheumatology Research
    Gilbert, Arizona 85297, United States
  • Arthritis & Rheumatology Research
    Mesa, Arizona 85210, United States
  • Arizona Arthritis & Rheumatology Research
    Phoenix, Arizona 85037, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Providence Saint John's Health Center
    Santa Monica, California 90404, United States
  • Medvin Clinical Research
    Thousand Oaks, California 91360, United States
  • Medvin Clinical Research
    Tujunga, California 91042, United States
  • University of Colorado Division of Rheumatology
    Aurora, Colorado 80045, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Bradenton Research Center
    Bradenton, Florida 34205, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • LIFE Clinical Trials
    Margate, Florida 33063, United States
  • D&H National Research Centers
    Miami, Florida 33155, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • Napa Research Center
    Pompano Beach, Florida 33064, United States
  • D&H Tamarac Research Centers
    Tamarac, Florida 33321, United States
  • GCP Clinical Research
    Tampa, Florida 33064, United States
  • ClinPro Research Solutions
    Tampa, Florida 33609, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • MedPharmics, LLC
    Metairie, Louisiana 70006, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Santa Fe Rheumatology
    Santa Fe, New Mexico 87505, United States
  • Long Island Arthritis & Osteoporosis Care
    Babylon, New York 11702, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • Cape Fear Arthritis Care
    Leland, North Carolina 28451, United States
  • PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • Shelby Clinical Research, LLC
    Shelby, North Carolina 28150, United States
  • Velocity Clinical Research Cincinnati
    Cincinnati, Ohio 45242, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Chattanooga Research & Medicine PLLC (CHARM)
    Chattanooga, Tennessee 37404, United States
  • Abigail Rebecca Neiman, MD, PA
    Houston, Texas 77024, United States
  • Pioneer Research Solutions Inc - Houston
    Houston, Texas 77099, United States
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah 84088, United States
  • Western Washington Medical Group
    Bothell, Washington 98021, United States
  • Arthritis Northwest
    Spokane, Washington 99204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jan 2024, 39 months.

Results were first posted in Jan 2025, 11 months after primary completion.

Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 13, 2020
StartActual
Oct 2, 2020
Primary completionActual
Jan 18, 2024
CompletionActual
Mar 25, 2024
Results first posted
Jan 7, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04511702
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Oct 2, 2020
Primary completion
Jan 18, 2024
Completion
Mar 25, 2024
Results posted
Jan 7, 2025
Last update
Oct 20, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion